Emergency BU Alert BU Medical Campus OPEN Jan. 28, 2015 Boston University Medical Campus will be open Wednesday, Jan. 28, 2015. BUSM classes will be held as scheduled. Staff should check with their managers regarding work schedules. Medical, PA and GMS students who are assigned to inpatient services or clinics are expected to be present, if possible. Students who are assigned to outpatient services should check with their course director or the policy at the clinical site. GMS classes are canceled. Staff should check with their manager regarding their work schedules. The Henry M. Goldman School of Dental Medicine will follow normal school hours. All Patient Treatment Centers will be open for patient care and all classes will be held as scheduled. BU School of Public Health classes are canceled; SPH non-essential staff may telecommute. Employees who are part of the BUMC parking program should park in your assigned lot or garage. The Boston parking ban is still in effect. For updated information, please call the weather/emergency hotline at 617-638-6886 or visit the BU Emergency Communications website at http://www.bu.edu/ehs/comm/

Richard P. Junghans

Richard P. Junghans

Associate Professor of Medicine


MD, University of Miami

PhD, University of California, Berkley

General field of research:

Immunology; Oncology; Gene Therapy

Affiliations other than medicine:

Evans Center for Interdisciplinary Biomedical Research

Roger Williams Medical Center Director, Biotherapeutics Development Lab

Contact information:

825 Chalkstone Avenue Providence, RI 02908



T cells Immunotherapy; Gene Therapy

Summary of research interest:

Richard P. Junghans, Ph.D., M.D., Associate Professor of Medicine, Boston University School of Medicine, is Director, Biotherapeutics Development Lab (BDL).  Dr. Junghans brings dual backgrounds in basic science and clinical medicine to a research program in clinical translational research.  He obtained his MD (U Miami) and training in Internal Medicine (Georgetown) and Hematology-Oncology (NCI/NIH), where he trained in immunology with Dr Thomas Waldmann, and his Ph.D. in Molecular Biology (UC Berkeley) in which his thesis described activities of retrovirus reverse transcriptases.

He applies molecular engineering techniques to develop new immunotherapies to treat cancer and infectious diseases, and is a rec0gnized leader in the field of cancer gene therapy.  He has completed Institutional Review Board applications, initiated Phase I and Phase II human clinical trials, secured FDA Investigational New Drug (IND) status for antibody and gene therapy agents and previously established an on-campus facility for gene therapy applications.  Dr. Junghans has more than 70 publications.  He is Board Certified in Internal Medicine and Medical Oncology and Board Eligible in Hematology.